@inproceedings{inproceedings, title  = {{Spirit 2: Final 5 Year Analysis of the UK National Cancer Research Institute Randomized Study Comparing Imatinib with Dasatinib in Patients with Newly Diagnosed Chronic Phase CML}},

 publisher = {{American Society of Hematology}},

 url = {{}},

 year = {{2018}},

 month = {{11}},

 author = {{O'Brien S and Cork L and Bandeira V and Bescoby R and Foroni L and Alaily L and Osborne W and Bell-Gorrod H and Latimer N and Apperley J and Hedgley C et al}},

 doi = {{10.1182/blood-2018-99-110128}},

 volume = {{132}},

 journal = {{Blood}},

 issue = {{Supplement 1}},

 pages = {{457-457}},

 note = {{Accessed on 2024/12/22}}}